Hostname: page-component-5447f9dfdb-97xxw Total loading time: 0 Render date: 2025-07-29T01:51:23.073Z Has data issue: false hasContentIssue false
  • English
  • Français

The Present Status of Monoamine Oxidase Inhibitors

Published online by Cambridge University Press:  29 January 2018

C. M. B. Pare
C. M. B. Pare*
Affiliation:
St. Barthomew's Hospital, West Smithfield, London EC1A 7BE
Get access Rights & Permissions [Opens in a new window]

Summary

The present status of monoamine oxidase inhibitors in the treatment of depression is reviewed. With adequate doses they are effective antidepressants, but dosages have in the past been too low. Provided proper dietary precautions are taken, the incidence of fatality from dietary interactions is very small and should not deter doctors from using these drugs, especially in those depressed patients who do not respond to tricyclic-type antidepressants. The present status of combining monoamine oxidase inhibitors with tricyclics is discussed, as are the newer specific inhibitors particularly clorgyline and deprenyl.

Information

Type
Review Article
Information
The British Journal of Psychiatry , Volume 146 , Issue 6 , June 1985 , pp. 576 - 584
Copyright
Copyright © 1985 The Royal College of Psychiatrists 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Aarons, S. F., Mann, J. J., Frances, A., Kocsis, J. & Young, R. C. (1984) Antidepressant effect of L-deprenyl: relative contribution of MAO A versus MAO B inhibition. Abstract, Collegium International, Neuro-Psychopharmacologium 14th C.I.N.P. Congress, Florence, June 1984.Google Scholar
Akindele, M. A. O., Evans, J. I. & Oswald, I. (1970) Monoamine oxidase inhibitors; sleep and mood. Electroencephalography and Clinical Neurophysiology, 29, 47–56.Google Scholar
Ananth, J. & Luchins, D. (1977) A Review of combined tricyclic and MAOI therapy. Comprehensive Psychiatry, 18, 221–230.Google Scholar
Beaumont, G. (1973) Clomipramine (Anafranil) in the treatment of pain, enuresis and anorexia nervosa. Journal of International Medical Research, 1, 435–437.CrossRefGoogle Scholar
Bevan Jones, A. B., Pare, C. M. B., Nicholson, W. J., Price, K. & Stacey, R. S. (1972) Brain amine concentrations after monoamine oxidase inhibitor administration. British Medical Journal, i, 17–19.CrossRefGoogle Scholar
Bhat, A. V., Rowan, P. R. & Paykel, E. S. (1984) Responses to phenelzine and amitriptyline absence of differential predictors by multiple regression analysis. Journal of Affective Disorders, 6, 209–218.CrossRefGoogle ScholarPubMed
Bieck, P. R., Cremer, G., Gleiter, C. & Antonin, K. H. (1982) Effect of the reversible MAO-Inhibitor CGP 11305 A on blood pressure respnse after oral tyramine. II World Conference on Clinical Pharmacology and Therapeutics. Washington D.C. 31 July – 5 August 1983.Google Scholar
Birkmayer, W., Riederer, P., Linauer, W. & Knoll, J. (1984) L-deprenyl plus L-phenylalanine in the treatment of depression. Journal of Neurological Transmission, 59, 81–87.CrossRefGoogle ScholarPubMed
Charney, D. S., Menkes, D. B. & Heninger, G. R. (1981) Receptor sensitivity and the mechanism of action of antidepressant treatment. Archives of General Psychiatry, 38, 1160–1180.Google Scholar
Cohen, R. M., Ebstein, R. P., Daly, J. W. & Murphy, D. L. (1982) Chronic effects of amonoamine oxidase-inhibiting antidepressant: decreases in functional alpha-adrenergic autoreceptors precede the decrease in norepinephrine-stimulated cyclic adenosine 3′:5′-Monophosphate systems in rat brain. The Journal of Neuroscience, 2, 1588–1595.CrossRefGoogle Scholar
Cooper, T. B., Jindal, S. P., Robinson, D. S. & Corcella, J. (1984) Metabolism of phenelzine in man: Lack of evidence for acetylation pathway. Abstract, Collegium International, Neuro-psychopharmacologium 14th C.I.N.P. Congress, Florence, June 1984.Google Scholar
Dally, P. J. (1960) Comparative trial of phenelzine and other antidepressant drugs in depression. In Symposium on Depression, London: Royal College of Surgeons.Google Scholar
Dally, P. J. & Rhode, P. (1961) Comparison of antidepressant drugs in depressive illness. Lancet, i, 18.Google Scholar
Davidson, J., McLeod, M. N. & Blum, R. (1978) Acetylation phenotype, platelet monoamine oxidase inhibition, and the effectiveness of phenelzine in depression. American Journal of Psychiatry, 135, 467–469.Google Scholar
Davidson, J. Weiss, J., Sullivan, J., Turnbull, C. & Linnoila, M. (1981a) A placebo controlled evaluation of isocarboxazid in out-patients. In Monoamine Oxidase Inhibitors – The State of the Art, (eds. Youdim, M. B. H. & Paykel, E. S.) Chichester: John Wiley.Google Scholar
Davidson, J. McLeod, M. M. N., Turnbull, C. D. & Miller, R. D. (1981b) A comparison of phenelzine and Imipramine in depressed inpatients. Journal of Clinical Psychiatry, 42, 10.Google Scholar
Davidson, J. & Turnbull, C. (1983) Isocarboxazid—efficacy and tolerance. Journal of Affective Disorders, 5, 183–189.Google Scholar
Evans, D. A. P., Davidson, K. & Pratt, R. T. C. (1965) The influence of acetylator phenotype on the effects of treating depression with phenelzine. Clinical Pharmacology and Therapeutics, 6, 430–435.Google Scholar
Ganrot, P. O., Rosengren, E. & Gottfries, C. G. (1962) Effect of iproniazid on monoamine and monoamine oxidase in human brain. Experientia, 16, 260–261.Google Scholar
Georgotas, A., Mann, J. & Friedman, E. (1981) Platelet monoamine oxidase inhibition as a potential indicator of favourable response to MAOI's in geriatric depressions. Biological Psychiatry, 16, 997–1001.Google Scholar
Georgotas, A. Friedman, E., McCarthy, M., Mann, J., Krakowski, M., Siegel, R. & Ferris, S. (1983) Resistant geriatric depressions and therapeutic respnse to monoamine oxidase inhibitors. Biological Psychiatry, 18, 195–205.Google Scholar
Giller, E., Bialos, D., Riddle, M., Sholomskas, A. & Harkness, L. (1982) Monoamine oxidase inhibitor-responsive depression. Psychiatry Research, 6, 41–48.Google Scholar
Green, R. & Youdim, M. (1976) Use of a behavioural model to study the action of monoamine oxidase inhibition in vivo. In: Monoamine Oxidase and its Inhibition. Ciba Foundation Symposium, 39, Amsterdam North Holland: Elsevier Excerpta Medica.Google Scholar
Hamilton, M. (1974) Drug resistant depressions: respnse to ECT Pharmakopsychiatrie Neuro-Psychopharmakologie, 7, 205–206.CrossRefGoogle Scholar
Hamilton, M. (1982) The effect of treatment in the melancholias (depressions). British Journal of Psychiatry, 140, 223–230.Google Scholar
Johnston, J. P. (1968) Some observations upon a new inhibitor of monoamine oxidase in brain tissue. Biochemical Pharmacology, 17, 1285–1297.CrossRefGoogle ScholarPubMed
Johnstone, E. D. (1976) The relationship between acetylator status and inhibition of monoamine oxidase, excretion of free drug and antidepressant response in depressed patients on phenelzine. Psychopharmacologia, 46, 289–294.Google Scholar
Johnstone, E. D. & Marsh, W. (1973) Acetylator status and respnse to phenelzine in depressed patients. Lancet, i, 567–570.Google Scholar
Kelly, D., Guirguis, W., Frommer, E., Mitchell-Heggs, N. & Sargant, , (1970) Treatment of phobic states with antidepressants. British Journal of Psychiatry, 116, 387–398.Google Scholar
Kelly, D. (1973) Progress in anxiety states. Proceedings Royal Society of Medicine, 66, 252–255.Google Scholar
Kety, S. (1976) Introduction. In Monoamine Oxidase and its Inhibition. Ciba Foundation Symposium, 39, Amsterdam: North Holland, Elsevier Excerpta Medica.Google Scholar
Liebowitz, M. R. & Klein, D. F. (1979) Hysteroid dysphoria. Psychiatric Clinics of North America, 2, 555–575.CrossRefGoogle Scholar
Liebowitz, M. R. Quitkin, F. M., Stewart, J. W., McGrath, P. J., Harrison, W., Rabkin, J., Tricamo, E., Markowitz, J. S. & Klein, D. F. (1984) Phenelzine v imipramine in atypical depression. Archives of General Psychiatry, 41, 669–677.Google Scholar
Lipper, S., Murphy, D. L., Slater, S. & Buchsbaum, M. S. (1979) Comparative behavioural effects of clorgyline and pargyline in man: a preliminary evaluation. Psychopharmacology, 62, 123–128.Google Scholar
Lips Edge, M. S., Hajioff, J., Huggins, P., Napier, L., Pearce, J., Pike, D. J. & Rich, M. (1973) The management of Severe Agoraphobia: a comparison of iproniazid and systematic desensitization. Psychopharmacologia (Berl) 32, 67–80.CrossRefGoogle Scholar
McGilchrist, J. M. (1975) Interactions with monoamine oxidase inhibitors. British Medical Journal, iii, 591–592.Google Scholar
Maclean, R., Nicholson, W. J., Pare, C. M. B., & Stacey, R. S. (1965) Effect of monoamine oxidase inhibitors on the concentrations of 5-hyroxytryptamine in the human brain. Lancet, 2, 205–208.CrossRefGoogle Scholar
Mann, J. J., Frances, A., Kaplan, R. D., Kocsis, J., Peselow, E. D. & Gershon, S. (1982) The relative efficacy of 1-deprenyl, a selective monoamine oxidase type B inhibitor, in endogenous and nonendogenous depression. Journal of Clinical Psychopharmacology, 2, 54–57.Google Scholar
Marks, J. (1965) Interactions involving drugs used in psychiatry. In The Scientific Basis of Drug Therapy in Psychiatry, (eds. Marks, J. & Pare, C. M. B.), Oxford: Pergamon Press.Google Scholar
Marley, E. & Wozniack, K. M. (1983) Clinical and experimental aspects of interactions between amine oxidase inhibitors and amine reuptake inhibitors. Psychological Medicine, 13, 735–749.Google Scholar
Marshall, E. F. (1976) The myth of phenelzine acetylation. British Medical Journal, 2, 817.Google Scholar
Marshall, E. F. Mountjoy, C. Q., Campbell, I. C., Garside, R. F., Leitch, I. M. & Roth, M. (1978) The influence of acetylator phenotype on the outcome of treatment with phenelzine, in a clinical trial. British Journal of Clinical Pharmacology, 6, 247–254.Google Scholar
Medical Research Centre Trial (1965) Clinical trial of the treatment of depressive illness. British Medical Journal, 1, 881–886.Google Scholar
Mendis, N., Pare, C. M. B., Sandler, M., Glover, V. & Stern, G. M. (1981a) Is the failure of (–) de prenyl, a selective monoamine oxidase B Inhibitor, to alleviate depression related to freedom from the cheese effect? Psychopharmacology, 73, 87–90.Google Scholar
Marshall, E. F. Pare, C. M. B., Sandler, M. & Glover, V. (1981b) (–) – Deprenyl in the treatment of depression. In Monoamine Oxidase Inhibitors – The Sate of the Art. (eds. Youdim, M. B. H. & Paykel, E. S.) Chichester: John Wiley.Google Scholar
Mendlewicz, J., & Youdim, M. B. H. (1983) L-Deprenyl, a selective monoamine oxidase type B inhibitor, in the treatment of depression: A double blind evaluation. British Journal of Psychiatry, 142, 508–511.Google Scholar
Murphy, D. L. (1981) Clinical, genetic, hormonal and drug influences on the activity of human platelet monoamine oxidase. In Monoamine Oxidase and its Inhibition. Ciba Foundation Symposium, 39, Amsterdam: North Holland, Elsevier Excerpta Medica.Google Scholar
Murphy, D. L. Upper, S., Pickar, D., Jimerson, D., Cohen, R. M., Garrick, N. A., Alterman, I. S. & Campbell, I. C. (1981) Selective inhibition of monoamine oxidase type A; clinical antidepressant effects and metabolic changes in man. In Monoamine Oxidase Inhibitors; – The State of the Art, (eds. Youdim, M. B. H. & Paykel, E. S.) Chichester: John Wiley.Google Scholar
Murphy, D. L. Cohen, R. M., Siever, L. J., Roy, B., Karoum, F., Wyatt, R. J., Garrick, N. A. & Linoila, M. (1983) Clinical and laboratory studies with selective monoamine-oxidase-inhibiting drugs. Modem Problems of Pharmacopsychiatry, 19, 287–303.Google Scholar
Nies, A., Robinson, D. S. & Lamborn, K. R. (1974) The efficacy of the MAO inhibitor, phenelzine, dose effects and predictions of response. In Neuropsychopharmacology (eds. Boissier, J. R., Hippius, H. & Pichot, P.). Amsterdam: Excerpta Medica.Google Scholar
Nies, A. & Robinson, M. D. (1981) Comparison of clinical effects of amitriptyline and phenelzine treatment. In Monoamine Oxidase Inhibitors – The State of the Art (eds. Youdim, M.B.H. & Paykel, E. S.). Chichester: John Wiley.Google Scholar
Nies, A. & Robinson, M. D. (1982) Monoamine oxidase inhibitors, In Handbook of Affective Disorders, (ed. Paykel, E. S.) Edinburgh: Churchill Livingstone.Google Scholar
Nolen, W (1984) Effects of oxaprotiline, fluvoxamine, sleep deprivation, 5-HTP and tranylcypromine in resistant depression. Abstract, Collegium International, Neuro-Psychopharmacologium 14th CINP Congress, Florence, June 1984.Google Scholar
Ogren, S. O. K., Fuxe, , Agnati, L. F., Gustafsson, J. A., Jonsson, G & Holm, A. C. (1979) Re-evaluation of the indoleamine hypothesis of depression. Evidence for a reduction of functional activity of central 5HT systems by antidepressant drugs. Journal of Neurological Transmission, 46, 85.Google Scholar
Pare, C. M. B. (1965) Some clinical aspects of antidepressant drugs. In The Scientific Basis of Drug Therapy in Psychiatry, 103–113. (eds. Marks, J. & Pare, C. M. B.) Oxford: Pergamon Press.Google Scholar
Pare, C. M. B. (1976) Introduction: clinical aspects of monoamine oxidase inhibitors in the treatment of depression. In Monoamine Oxidase and its Inhibition, Ciba Foundation Symposium, 39, 271–296.Google Scholar
Pare, C. M. B. (1977) Monoamine oxidase inhibitors; a personal account. In Handbook of studies on depression, (ed. Burrows, G. D.) Amsterdam: Excerpta Medica.Google Scholar
Pare, C. M. B., Kline, N., Hallstrom, C., Cooper, T. B. (1982) Will Amitriptyline prevent the “cheese” reaction of monoamine oxidase inhibitors? Lancet, 2, 183–186.Google Scholar
Paykel, E. S., West, P. S. Rowan, P. R. & Parker, R. R. (1982) Influence of acetylator phenotype on antidepressant effects of phenelzine. British Journal of Psychiatry, 141, 243–248.Google Scholar
Pohl, R., Berchou, R. & Rainey, J. M. Jr. (1982) Tricyclic antidepressants and monoamine oxidase inhibitors in the treatment of agoraphobia. Journal of Clinical Psychopharmacology, 2, 399–407.Google Scholar
Pollit, J. & Young, J. (1971) Anxiety state or masked depression? A study based on the action of monoamine oxidase inhibitors. British Journal of Psychiatry, 119, 143–149.Google Scholar
Ravaris, C. L., Nies, A., Robinson, D. S., Ives, J. O., Lamborn, K. R. & Korson, L. (1976) A multiple-dose controlled study of phenelzine in depressive-anxiety states. Archives of General Psychiatry, 33, 347–350.CrossRefGoogle Scholar
Ravaris, C. L. Robinson, D. S., Ives, J. O., Nies, A. & Bartlett, D. (1980) A comparison of phenelzine and amitriptyline in the treatment of depression. Archives of General Psychiatry, 37, 1075–1080.Google Scholar
Razani, J., White, K., White, J., Simpson, G., Sloane, R. B., Rebal, R. & Palmer, R. (1983) The safety and efficacy of combined Amitriptyline and tranylcypromine antidepressant treatment. Archives of General Psychiatry, 40, 657–661.Google Scholar
Robinson, D. S., Nies, A., Ravaris, C. L. & Lamborn, K. R. (1973). The monoamine oxidase inhibitor, phenelzine, in the treatment of depressive anxiety states. Archives of General Psychiatry, 29, 407–413.Google Scholar
Robinson, D. S., Nies, A., Ravaris, C. L. Ives, J. O. & Bartlett, D. (1978a) Clinical psychopharmacology of phenelzine: MAO activity and clinical response. In Psychopharmacology: A Generation of Progress, (eds Lipton, M. A., DiMascio, A. & Killam, K. F.), New York: Raven Press.Google Scholar
Robinson, D. S., Nies, A., Ravaris, C. L. Ives, J. O. & Bartlett, D. (1978b) Clinical pharmacology of phenelzine. Archives of General Psychiatry, 35, 629–635.Google Scholar
Rowan, P. R., Paykel, E. S. & Parker, R. R. (1982) Phenelzine and amitriptyline: effects on symptoms of neurotic depression. British Journal of Psychiatry, 140, 475–483.Google Scholar
Sethna, E. R. (1974) A study of refractory cases of depressive illness and their response to combined antidepressant treatment. British Journal of Psychiatry, 124, 265–272.Google Scholar
Shaw, D. M. (1977) The practical management of affective disorders. British Journal of Psychiatry, 130, 432–451.Google Scholar
Sheehan, D. V., Ballenger, J. & Jacobsen, G. (1980) Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. A rchives of General Psychiatry, 37, 51–59.Google Scholar
Shuckit, M., Robins, E. & Feighner, J. (1971) Tricyclic antidepressants and monoamine oxidase inhibitors. Combined therapy in the treatment of derpession. Archives of General Psychiatry, 24, 509.Google Scholar
Solyom, L., Heseltine, G. F. D., McClure, D. J., Solyom, C., Ledwidge, B. & Steinberg, G. (1973) Behaviour therapy versus drug therapy in the treatment of phobic neuroses. Canadian Psychiatric Association Journal, 18, 25–31.Google Scholar
Stolz, J. F., Marsden, C. A. (1982) Withdrawal from chronic treatment with metergoline dl-Propranolol and Amitriptyline enhances serotonin receptor mediated behaviour in the rat. European Journal of Pharmacology, 79, 17–22.Google Scholar
Sulser, F., Janowsky, A. J., Okada, F., Manier, D. H. & Mobley, P. L. (1983) Regulation of recognition and action function of the norepinephrine (NE) receptor-coupled adenylate cyclase system in brain: implications for therapy of derpession. Neuropharmacology, 22, 425–431.CrossRefGoogle Scholar
Tilstone, W. J., Margot, P. & Johnstone, E. C. (1979) Acetylation of phenelzine. Psychopharmacology, 60, 261–263.Google Scholar
Tyrer, P. (1973) Are Monoamine oxidase inhibitors antidepressants? Proceedings, Royal Society of Medicine, 66, 950–951.Google Scholar
Tyrer, P. Candy, J. & Kelly, D. (1973a) A study of the clinical effects of phenelzine and placebo in the treatment of phobic anxiety. Psychopharmacologia, 32, 237–254.Google Scholar
Tyrer, P. Candy, J. & Kelly, D. (1973b) Phenelzine in phobic anxiety: a controlled trial. Psychological Medicine, 3, 120–124.Google Scholar
Tyrer, P. (1976) Towards rational therapy with monoamine oxidase inhibitors. British Journal of Psychiatry, 128, 354–360.Google Scholar
Tyrer, P. Gardner, M., Lambourn, J. & Whitford, M. (1980) Clinical and pharmacokinetic factors affecting response to phenelzine. British Journal of Psychiatary, 136, 359–365.Google Scholar
Tyrer, P. Gardner, M., Lambourn, J. & Whitford, M. (1981) Dosage and acetylator status in clinical response to phenelzine. In Monoamine Oxidase Inhibitors. The State of the Art. (eds Youdim, M. B. H. & Paykel, E. S.), Chichester: John Wiley.Google Scholar
Van Praag, H. M. (1983) Insearch of the mode of action of antidepressants 5-HTP/Tyrosine mixture in derpression. Neuropharmacology, 22, 433–440.Google Scholar
West, E. D. & Dally, P. J. (1959) Effects of iproniazid on depressive syndromes. British Medical Journal, i, 1491–1494.Google Scholar
White, K & Simpson, G. (1981) Combined MAOI-tricyclic antidepressant treatment, a reevaluation. Journal of Clinical Psychopharmacology, 1, 264–282.Google Scholar
Yates, C. M. & Loudin, J. B. (1979) Acetylator status and inhibition of platelet monoamine oxidase following treatment with phenelzine. Psychological Medicine, 9, 777–779.Google Scholar
Youdim, M. B. H., Collins, C. G. S., Sandler, M., Bevan Jones, A. B., Pare, C. M. B. & Nicholson, W. J. (1972) Human brain monoamine oxidase: multiple forms and selective inhibitors. Nature, (Lond) 263, 225–228.Google Scholar
Young, J. P. R., Lader, M. H., Hughes, W. C. (1979) Controlled trial in trimipramine monoamine oxidase inhibitors and combined treatment in depressed out patients. British Medical Journal, 2, 1315–1317.Google Scholar
Zisook, S. (1983) Isocarboxazid in the treatment of depression. American Journal of Psychiatry, 146, 792–794.Google Scholar
Submit a response

eLetters

No eLetters have been published for this article.